Literature DB >> 34125914

Upregulation of RNA cap methyltransferase RNMT drives ribosome biogenesis during T cell activation.

Alison Galloway1, Aneesa Kaskar1, Dimitrinka Ditsova1, Abdelmadjid Atrih2, Harunori Yoshikawa1, Carolina Gomez-Moreira1, Olga Suska1, Marcin Warminski3, Renata Grzela4, Angus I Lamond1, Edward Darzynkiewicz4, Jacek Jemielity3, Victoria H Cowling1.   

Abstract

The m7G cap is ubiquitous on RNAPII-transcribed RNA and has fundamental roles in eukaryotic gene expression, however its in vivo role in mammals has remained unknown. Here, we identified the m7G cap methyltransferase, RNMT, as a key mediator of T cell activation, which specifically regulates ribosome production. During T cell activation, induction of mRNA expression and ribosome biogenesis drives metabolic reprogramming, rapid proliferation and differentiation generating effector populations. We report that RNMT is induced by T cell receptor (TCR) stimulation and co-ordinates the mRNA, snoRNA and rRNA production required for ribosome biogenesis. Using transcriptomic and proteomic analyses, we demonstrate that RNMT selectively regulates the expression of terminal polypyrimidine tract (TOP) mRNAs, targets of the m7G-cap binding protein LARP1. The expression of LARP1 targets and snoRNAs involved in ribosome biogenesis is selectively compromised in Rnmt cKO CD4 T cells resulting in decreased ribosome synthesis, reduced translation rates and proliferation failure. By enhancing ribosome abundance, upregulation of RNMT co-ordinates mRNA capping and processing with increased translational capacity during T cell activation.
© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Year:  2021        PMID: 34125914     DOI: 10.1093/nar/gkab465

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  8 in total

1.  CMTR1 is recruited to transcription start sites and promotes ribosomal protein and histone gene expression in embryonic stem cells.

Authors:  Shang Liang; Joana C Silva; Olga Suska; Radoslaw Lukoszek; Rajaei Almohammed; Victoria H Cowling
Journal:  Nucleic Acids Res       Date:  2022-03-21       Impact factor: 16.971

Review 2.  How RNA modifications regulate the antiviral response.

Authors:  Matthew G Thompson; Matthew T Sacco; Stacy M Horner
Journal:  Immunol Rev       Date:  2021-08-17       Impact factor: 12.988

3.  Efficient and Rapid Analysis of Polysomes and Ribosomal Subunits in Cells and Tissues Using Ribo Mega-SEC.

Authors:  Harunori Yoshikawa; Ramasubramanian Sundaramoorthy; Daniel Mariyappa; Hao Jiang; Angus I Lamond
Journal:  Bio Protoc       Date:  2021-08-05

4.  Risk Model and Immune Signature of m7G-Related lncRNA Based on Lung Adenocarcinoma.

Authors:  Chuanhao Zhang; Dong Zhou; Zhe Wang; Zaishuang Ju; Jiabei He; Genghao Zhao; Ruoyu Wang
Journal:  Front Genet       Date:  2022-06-08       Impact factor: 4.772

Review 5.  Protein synthesis, degradation, and energy metabolism in T cell immunity.

Authors:  Julia M Marchingo; Doreen A Cantrell
Journal:  Cell Mol Immunol       Date:  2022-01-04       Impact factor: 22.096

Review 6.  RNA modifications: importance in immune cell biology and related diseases.

Authors:  Lian Cui; Rui Ma; Jiangluyi Cai; Chunyuan Guo; Zeyu Chen; Lingling Yao; Yuanyuan Wang; Rui Fan; Xin Wang; Yuling Shi
Journal:  Signal Transduct Target Ther       Date:  2022-09-22

7.  Prognostic value of 12 m7G methylation-related miRNA markers and their correlation with immune infiltration in breast cancer.

Authors:  Wenchuan Zhang; Shuwan Zhang; Zhe Wang
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

8.  Comprehensive analysis of m7G modification patterns based on potential m7G regulators and tumor microenvironment infiltration characterization in lung adenocarcinoma.

Authors:  Shouzheng Ma; Jun Zhu; Mengmeng Wang; Jianfei Zhu; Wenchen Wang; Yanlu Xiong; Runmin Jiang; Lei Liu; Tao Jiang
Journal:  Front Genet       Date:  2022-09-29       Impact factor: 4.772

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.